A pproximately 60% of all cardiac deaths are attributable to out-of-hospital sudden cardiac death. Although resuscitation efforts are effective in restoring a pulse in 30% to 40% of victims of cardiac arrest, the eventual hospital discharge rate is Ͻ5% (1, 2) . In-hospital death is usually the result of ischemic brain injury, multiorgan failure, or cardiac dysfunction (3) . Postresuscitation myocardial dysfunction has been reported in experimental cardiac arrest models and the clinical population and potential mechanisms are defined (4) . Despite the prevalence of postresuscitation myocardial dysfunction in successfully resuscitated patients and its potential contribution to early mortality, few studies have addressed its etiology or management (5) (6) (7) (8) .
Ischemia/reperfusion injury has been characterized as a multifactorial antigenindependent inflammatory condition in which accelerated proinflammatory cytokine synthesis and release are commonly observed (9, 10) . Tumor necrosis factor (TNF)-␣ and interleukin (IL)-1␤ are proinflammatory cytokines known to decrease myocardial contractility (11) . Observational clinical studies in small series of patients have demonstrated elevated TNF-␣ and IL-1␤ levels in patients resuscitated from cardiac arrest (12, 13) . TNF-␣ is elevated at the time of initial sampling after resuscitation and hospital admission and remains elevated in those patients who eventually die in the hospital or who require catecholamines for hemodynamic support. A recent laboratory study in a porcine cardiac arrest and resuscitation model demonstrated an inverse relationship between plasma TNF-␣ concentrations and myocardial contractility, measured as left ventricular (LV) rate of increase of pressure over time (14) . The purpose of this study was to determine whether blocking TNF-␣ after resuscitation from prolonged cardiac arrest would prevent postresuscitation myocardial dysfunction.
MATERIALS AND METHODS
This investigation was approved by the Animal Care and Utilization Review Committee of our institution and conformed to the National Institutes of Health policy on humane care and use of laboratory animals.
Animals were purchased from an Association for Assessment and Accreditation of Laboratory Animal Care International-approved vendor for domestic swine. Objective: Left ventricular dysfunction after successful cardiopulmonary resuscitation contributes to early death after resuscitation. Proinflammatory cytokines are known to decrease myocardial function, and tumor necrosis factor-␣ has been shown to increase after successful resuscitation. We hypothesized that blocking the effects of tumor necrosis factor-␣ with infliximab would prevent or minimize postresuscitation cardiac dysfunction.
Design: Randomized, placebo-controlled comparative study. Setting: Large animal research laboratory. Subjects: Twenty-eight anesthetized and instrumented domestic male swine (Yorkshire and Yorkshire/Hampshire mix; weight, 35-45 kg).
Interventions: Infusion of infliximab (5 mg/kg) or normal saline after resuscitation from ventricular fibrillation cardiac arrest.
Measurements and Main Results: Hemodynamic variables, indices of left ventricular function, and tumor necrosis factor-␣ were measured before and after 8 mins of cardiac arrest during the early postresuscitation period (3 hrs). Within 5 mins of restoration of spontaneous circulation, 14 animals received infliximab, 5 mg/kg, infused over 30 mins. Fourteen animals received an infusion of normal saline. Inotropes and vasopressors were not administered to either group after resuscitation. Tumor necrosis factor-␣ increased after restoration of circulation and remained elevated throughout the observation period. Differences between groups were not significant. Interleukin-1␤ concentration did not change significantly during the observation period in either study group. Mean arterial pressure and stroke work were significantly greater in the infliximab group within 30 mins of resuscitation, and these differences were sustained throughout the 3-hr postresuscitation period. The effect of tumor necrosis factor-␣ blockade was evident only in animals with a significant increase (doubling) in plasma tumor necrosis factor-␣ at 30 mins after arrest.
Conclusion: Tumor necrosis factor-␣ plays a role in cardiac dysfunction after arrest and infliximab may attenuate or prevent postresuscitation myocardial dysfunction when administered immediately after resuscitation. (Crit Care Med 2010; 38:1162-1167) KEY WORDS: heart arrest; ventricular fibrillation; cardiopulmonary resuscitation; tumor necrosis factor; interleukin; hemodynamics Hampshire mix; weight, 35-45 kg) were premedicated with ketamine (20 mg/kg) and xylazine (2 mg/kg). General anesthesia was induced with isoflurane via nose cone and, after endotracheal intubation, maintained with inhaled isoflurane and nitrous oxide in a 1:1 mixture with oxygen. Minute ventilation was adjusted to maintain an end-tidal CO 2 of 35 to 45 mm Hg. Standard lead II of the surface electrocardiogram was monitored during instrumentation and throughout the study protocol.
Both external jugular veins and a femoral artery were surgically exposed and micromanometer-tipped catheters (Millar Instruments, Houston, TX) were inserted and positioned in the right atrium, LV, and aortic arch. The tip of a bipolar pacing catheter was positioned in contact with the right ventricular endocardium for induction of ventricular fibrillation (VF). A multilumen catheter thermistor (Edwards Lifesciences, Irvine, CA) was positioned in a branch of the pulmonary artery for thermodilution carbon monoxide determinations. Standard adhesive defibrillation electrode patches were applied to the left and right lateral aspects of the shaved thorax (Quick-Combo; Medtronic Emergency Response Systems, Redmond, WA). Transthoracic impedance was measured using a tetrapolar constant current impedance measuring system (THRIM, Morro Bay, CA). A small value noninductive resistor (30 ⍀) was then placed in series with the truncated exponential biphasic defibrillation waveform defibrillator (LifePak 12; Medtronic Emergency Response Systems, Redmond, WA).
After instrumentation, heart rate, core temperature (measured with thermistor catheter), systolic and diastolic aortic pressures, LV end-diastolic pressure, and cardiac output (measured in triplicate) were recorded and arterial blood was analyzed (I-Stat CG8ϩ; I-Stat Corp, Princeton, NJ). Mean arterial pressure (MAP) and stroke volume were derived using standard formulas. The time constant of isovolumic LV relaxation () was determined using commercially available software (Blood Pressure Module, version 1.0.3; ADInstruments, Colorado Springs, CO). Hemodynamic data were recorded and stored on a laptop computer using PowerLab Chart version 5.2 (ADInstruments). VF was then induced with a brief 60-Hz AC current pulse delivered to the right ventricular endocardium via the pacing catheter. After 7 mins of untreated VF, mechanical closed-chest compressions (Thumper; MI Instruments, Grand Rapids, MI) were begun with the animal in the supine position and were administered at a rate of approximately 100/min with force sufficient to depress the sternum 1.5 to 2.0 inches. Ventilation was not performed during the 1-min interval preceding the first countershock. Af-ter 1 min, electrical defibrillation was attempted with a biphasic waveform defibrillator (LifePak 12, Medtronic Emergency Response Systems, Redmond, WA). Three shocks were administered in an escalating energy sequence (200, 300, 360 J), if necessary. Chest compressions were performed between countershocks. If one of the first three countershocks terminated VF but resulted in a nonperfusing spontaneous cardiac rhythm, i.e., asystole or pulse electrical activity, or if VF persisted after the first three shocks, then chest compressions were restarted and continued for 2 min or until return of spontaneous circulation (ROSC). Animals not resuscitated within 2 min were administered intravenous epinephrine (0.01 mg/kg) every 5 to 8 mins and cardiopulmonary resuscitation continued until spontaneous perfusing rhythm was established.
After resuscitation, animals were randomized into two groups using permuted block design. Control animals (n ϭ 14) were administered 250 mL of normal saline over 30 mins, beginning 5 mins after ROSC. Animals in the treatment group (n ϭ 14) were administered infliximab, a monoclonal anti-TNF-␣ antibody, at a dose of 5 mg/kg in 250 mL of normal saline infused over 30 mins beginning 5 mins after ROSC. No other drugs were administered or interventions performed during the ensuing 3-hr observation period after ROSC. Hemodynamic measurements and core temperature were made at 30, 60, 120, and 180 mins after ROSC.
Before VF induction and at 30, 60, 120, and 180 mins after restoration of circulation, arterial blood was sampled, placed in sterile, chilled (0°C), heparinized tubes, and centrifuged at 5000 rpm for 10 mins. Plasma was immediately separated and stored at Ϫ80°C until analysis. TNF-␣ and IL-1␤ concentrations were determined by a quantitative sandwich enzymelinked immunosorbent assay using commercially available kits specific for these porcine cytokines (R&D Systems, Minneapolis, MN).
Data Analyses
Statistical analyses were conducted using SAS version 9.1.3 (SAS Institute, Cary, NC).
Summary measures are reported as means and standard deviations for normal distributions or medians and interquartile ranges for nonnormal distributions. Student's t tests or Mann-Whitney rank-sum tests were used for comparing fixed time point variables between animals treated with saline and infliximab.
Generalized linear mixed models were used to evaluate associations between variables while accounting for the autocorrelation inherent in repeated measure designs. The SAS procedure, Proc Mixed, was used for this purpose, with time included as a random effect and other variables included as fixed effects. Variable selection was based on a priori assumptions and iterative fitting of potential models. Model fit and correlation structure specifications were assessed by Akaike Information Criteria. When making multiple postresuscitation comparisons with arrest values before arrest, p values were adjusted according to the method of Dunnett-Hsu (15). We considered an ␣ level of 0.05 to be significant.
RESULTS
Differences in hemodynamic variables before arrest were not observed between treatment groups (Table 1) . Similarly, variables associated with resuscitation outcome and postresuscitation ventricular function were likewise not significantly different ( Table 2) .
After resuscitation, TNF-␣ concentrations 30 and 60 mins after ROSC were significantly greater than values before arrest for both study groups. However, IL-1␤ levels did not vary significantly from values before arrest in either group. There was no statistically significant difference in the response of either TNF-␣ or IL-1␤ between treatment groups over time ( Figs. 1 and 2) . At 3 hrs postresuscitation, core temperature was not significantly different between groups (control group, 35.5 Ϯ 1.3°C; infliximab group, 35.6 Ϯ 3°C).
In a generalized linear mixed model, infliximab-treated animals had a MAP Values are the mean Ϯ SD or median and interquartile range. MAP, mean arterial pressure; LV, left ventricular; SW, stroke work; TNF-␣, tumor necrosis factor-␣; IL-1␤, interleukin-1␤. that was, on average, 8.7 mm Hg (95% confidence interval, 4.5-13.0 mm Hg; p ϭ .0001) higher than control animals. Treated animals also had a mean stroke work (SW) that was, on average, 9.1 gm-m (95% confidence interval, 5.4 -12.8 gm-m; p Ͻ .0001) higher than control animals. Postresuscitation hemodynamic variables are shown in Table 3 . Differences in mean values for MAP and SW are illustrated in Figure 3 . Systolic rate of increase of pressure over time was signif-icantly greater in the infliximab group at all postresuscitation time points and stroke volume was greater from 30 to 120 mins. TNF-␣ levels were inversely correlated with MAP (r ϭ Ϫ.41; p Ͻ .0001) and with SW (r ϭ Ϫ.37; p Ͻ .0001). IL-1␤, however, was not associated with either response (p Ͼ .11 for both associations).
When animals were classified into TNF-␣ producers (defined as at least a doubling of TNF-␣ at 30 mins when compared to values before arrest; n ϭ 15) and nonproducers (n ϭ 13) ( Fig. 4) , an association between infliximab treatment and higher MAP and SW was seen only within the TNF-␣ producer group. In this group, infliximab-treated animals had, on average, 10.8 mm Hg higher MAP (95% confidence interval, 5.5-16.1 mm Hg; p ϭ .0002) than controls. There was also an interaction between time and treatment assignment. This interaction resulted in a lessening of the treatment effect on MAP over time until there was no statistical difference in MAP between the two groups at the 180-min measurement. Infliximab treatment was also associated with higher SW in producers but not in nonproducers. SW among infliximab treated animals was, on average, 11.2 gm-m (95% confidence interval, 5.7-16.7 gm-m; p ϭ .0002) higher than controls. This effect was not time-varying in the model, with infliximab-treated animals having a consistently higher SW across all time points.
DISCUSSION
This study in a conventional porcine cardiac arrest model demonstrates that infliximab, a monoclonal anti-TNF-␣ antibody, administered after resuscitation, is effective in preserving hemodynamic indices of LV function. LV SW, a global measure of cardiac function, was significantly greater in the treatment group within 30 mins of successful resuscitation and hemodynamic differences persisted throughout the observation period. When animals were subsequently classified based on the TNF-␣ response after arrest, the beneficial effect of infliximab was most prominent in those animals with a significant increase in TNF after restoration of spontaneous circulation. These findings suggest that TNF-␣ plays a contributory role in myocardial dysfunction after arrest, one of the hallmarks of the postarrest syndrome.
TNF-␣ is known to cause myocardial depression, presumably by disrupting cal- Values are the mean Ϯ SD or median and interquartile range.
cium homeostasis or calcium sensitivity and the normal myocardial contractionrelaxation cycle (16, 17) . TNF-␣ may also induce a state of relative catecholamines insensitivity or refractoriness (18 -20) . The hemodynamic effects of TNF-␣ include depressed myocardial contractility, decreased ejection fraction, and ventricular dilation. The use of monoclonal antibodies to TNF-␣ in low doses (1 mg/kg) has been shown to minimize cardiac dysfunction in in vivo and isolated heart models of acute global and regional myocardial ischemia (21) . Infliximab is produced by a recombinant cell line and is a chimeric IgG1 monoclonal antibody composed of human constant and murine variable regions of TNF-␣. Porcine TNF shares a similar structure with that of human and murine TNF and exhibits cytotoxicity to target indicator cells (PK and L929) (15) at similar concentrations (22) . Porcine TNF-␣ cytotoxic activity can be totally neutralized with anti-human TNF monoclonal antibody (23) . Porcine TNF-␣ receptors likewise share a structure similar to that of humans, and mice and human soluble TNF-␣ receptors bind porcine TNF-␣ (24) . Considering these characteristics, binding to and neutralization of porcine TNF-␣ by infliximab would be expected.
We observed considerable variability in the TNF-␣ response to ischemia and reperfusion within the control and treatment groups. We postulate that this variable response is likely attributable to genetic polymorphism in the promoter region of the TNF-␣ gene. TNF-␣ single nucleotide polymorphism has been extensively studied in humans and is pos- tulated to play a role in susceptibility and response to infection and outcome (25) (26) (27) . Polymorphism would be expected in the typical outbred, mixed-breed swine used in research laboratories. This study has several limitations. Although the anatomy of the porcine coronary circulation is similar to that of humans, the absence of significant underlying atherosclerotic coronary artery disease and previous myocardial injury, both of which are usually present in resuscitated patients, is likely to have affected the extent of cardiac dysfunction after resuscitation. We used only male swine in this study because of previous observations suggesting that there are gender differences in the proinflammatory response after resuscitation and that the response is more dramatic and more predictable in males than females (28) . We evaluated one cardiac arrest duration (7 mins) before initiation of resuscitation efforts. A long duration of ischemia may have resulted in a more pronounced inflammatory response. The anesthetic agent necessary to conduct the study may also have impacted coronary vascular tone and baseline and postresuscitation LV function. Although statistically significant differences in energy required for defibrillation, time to restoration of spontaneous circulation, and epinephrine dose were not demonstrated, small differences might be physiologically significant and may have affected postresuscitation ventricular function. We evaluated only one dose of infliximab in this study. We selected a dose of 5 mg/kg because previous work in clinical trials indicated that 5 mg/kg did not produce immediate significant side effects when administered intravenously and approximates the dose used in large clinical trials of TNF-␣ blockade in sepsis (29, 30) . We did not evaluate the potential role of other cytokine inhibitors, e.g., an anti-IL-1␤ inhibitor, on postarrest cardiac dysfunction. However, IL-1␤ concentrations did not significantly vary during the 3-hr postarrest study period, were not associated with hemodynamic variables, and thus are unlikely to have contributed substantially to the observed hemodynamic depression. We did not attempt to control body temperature during the observation period and observed statistically insignificant differences in temperature between groups. Previous work in whole animal models subjected to hypothermia after cardiac arrest and hemorrhagic shock has not demonstrated a significant effect of hypothermia on the inflammatory response (31, 32) .
Anti-cytokine therapy has not been shown to be beneficial in some disease states characterized by increased cytokine production, specifically TNF-␣. Notably, infliximab and etanercept have not been shown to be consistently effective in the setting of chronic congestive heart failure or the sepsis syndrome and reasons for the lack of a positive effect have been enumerated (33, 34) . However, it is likely that the organism resuscitated from an acute, short-lived, global (total body) ischemic insult, i.e., cardiac arrest, represents a unique physiologic state characterized by an early and sustained maximal stress response and a unique proinflammatory cytokine response when compared to other more indolent insults (35) . The findings of this investigation in a commonly used porcine cardiac arrest model suggest that TNF-␣ plays a role in postresuscitation myocardial contractile dysfunction and that therapeutic interventions that inhibit its effects may attenuate to some degree but may not prevent its myocardial depressant properties. Other factors contribute to the postresuscitation myocardial dysfunction (4). Hemodynamic benefit appears to be dependent on the TNF-␣ response after resuscitation and reperfusion and are likely genotypically determined. TNF-␣ blockers, either alone or in combination with drugs that block other cytokines or their receptors, may be useful adjuncts in the management of the postarrest syndrome, particularly if the TNF-␣ or other cytokine blood levels are known early after resuscitation.
